MedTrace Logo

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

NCT00367016 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2021-07-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.

Conditions

Interventions

DRUG

Omalizumab

Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.

DRUG

Placebo

Placebo, given by subcutaneous injection.

Sponsors & Collaborators

  • University of California, Davis

    lead OTHER

Principal Investigators

  • Fu-Tong Liu, M.D., Ph.D. · University of California, Davis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2012-10-17
Completion
2012-10-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00367016 on ClinicalTrials.gov